Subscribe to our newsletter and stay informed

Check out our list of top companies

Check out our carefully compiled lists of the most relevant and impactful companies within their fields.

Check out our list of top unicorns

Read and learn about the biggest companies that various countries have produced, how they made it, and what the future looks like for them.
July 17, 2023

EG 427's €18M Series A fuels game-changing pinpoint gene therapies

EG 427: Pioneering French biotech wields unique nrHSV-1 vector platform!

Neurogenic bladder dysfunction, a chronic and perilous condition impacting individuals with spinal cord injuries or neurodegenerative diseases, has long demanded better treatment options. Existing drugs come with their limitations, often causing bladder muscle paralysis and related complications. But now, EG 427, a pioneering French biotech company, has unveiled a groundbreaking solution. Through its non-replicative Herpes Simplex Virus type 1 (nrHSV-1) based vector platform, EG 427 offers targeted and long-lasting disease-modifying therapies. With an additional €5 million secured in the Series A funding round, EG 427 is poised to revolutionize the field of DNA medicine. The funds will propel the advancement of their lead product, EG110A, towards clinical trials, offering hope for an innovative approach to neurogenic bladder dysfunction treatment.

EG110A represents a remarkable milestone in precision gene therapy. By leveraging the localized administration of nrHSV-1 vectors into the bladder muscle, EG110A achieves unparalleled specificity for targeted neurons, without systemic dispersion like other viral vectors used in gene therapy. This breakthrough not only promises enhanced efficacy but also potentially eliminates the need for repeated injections, offering long-term relief for patients.

The successful closing of the Series A funding round, totaling €18 million, has garnered significant support from both existing and new investors. Philippe Chambon, M.D., Ph.D., Founder, Chairman, and Chief Executive Officer of EG 427 expressed his delight, stating, "We are thrilled to conclude this round with strong backing from our current investors, while also welcoming new supporters." These funds will be instrumental in driving EG 427's pipeline forward, ultimately leading to the submission of an Investigational New Drug application in Q1 2024 for the first clinical study of their flagship product, EG110A.

With the unrivaled precision and potential long-term efficacy offered by nrHSV-1 vectors, EG110A holds the promise of transforming the lives of those suffering from neurogenic bladder dysfunction. As EG 427 continues to push the boundaries of gene therapy, this remarkable breakthrough could herald a new era in targeted treatments for debilitating conditions, ushering in a future where patients can enjoy a better quality of life.

Josefina Dipaolo
Josefina Dipaolo
Content Writer at TechNews180
Back to top

Related articles

chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram